SHUTTLE PHARMACEUTICALS HOLDINGS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of -$7.51 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-09-24.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-09-24
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was -$7.51K, a 116.03% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $35.02K, a 93.48% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $134.32K, a 196.67% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $46.85K, a 34.16% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $932.97K, a 259.19% increase from fiscal 2024.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $259.74K, a 42.75% increase from fiscal 2023.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $181.96K, a 23.40% decline from fiscal 2022.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $237.55K, a 43.44% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$7.51K 10-Q · filed 2026-09-24 | $27.51K derived: sum of 2 quarters · filed 2026-09-24 | |||
| 2026-03-31 | $35.02K 10-Q · filed 2026-09-24 | ||||
| 2025-12-31 | $932.97K 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $134.32K 10-Q · filed 2025-11-13 | $181.17K derived: sum of 2 quarters · filed 2025-11-13 | $718.22K derived: sum of 3 quarters · filed 2026-09-24 | ||
| 2025-06-30 | $46.85K 10-Q · filed 2025-11-13 | $583.90K derived: sum of 2 quarters · filed 2026-09-24 | |||
| 2025-03-31 | $537.05K 10-Q · filed 2026-09-24 | ||||
| 2024-12-31 | $259.74K 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | $45.27K 10-Q · filed 2025-11-13 | $116.44K derived: sum of 2 quarters · filed 2025-11-13 | $227.89K derived: sum of 3 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $71.16K 10-Q · filed 2025-11-13 | $182.61K derived: sum of 2 quarters · filed 2025-11-13 | |||
| 2024-03-31 | $111.45K 10-Q · filed 2025-11-13 | ||||
| 2023-12-31 | $181.96K 10-K · filed 2025-02-26 | ||||
| 2023-09-30 | $37.58K 10-Q · filed 2024-11-13 | $87.11K derived: sum of 2 quarters · filed 2024-11-13 | $95.44K derived: sum of 3 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $49.52K 10-Q · filed 2024-11-13 | $57.85K derived: sum of 2 quarters · filed 2024-11-13 | |||
| 2023-03-31 | $8.33K 10-Q · filed 2024-11-13 | ||||
| 2022-12-31 | $237.55K 10-K/A · filed 2024-09-04 | $403.96K 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $23.67K 10-Q · filed 2023-11-13 | $190.20K derived: sum of 2 quarters · filed 2023-11-13 | $356.73K derived: sum of 3 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $166.53K 10-Q · filed 2023-11-13 | $333.07K derived: sum of 2 quarters · filed 2023-11-13 | |||
| 2022-03-31 | $166.53K 10-Q · filed 2023-11-13 | ||||
| 2021-12-31 | $420.00K 10-K · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |